Abstract
Aspirin is the most widely employed antithrombotic agent in use today and has a proven role in the prevention and acute management of atherosclerosis-associated arterial thrombotic events. More recently developed antiplatelet agents have been found to have specific prophylactic roles associated with percutaneous coronary intervention and other clinical settings. This article outlines pharmacologic considerations and current clinical knowledge relevant to the use of aspirin, ticlopidine, clopidogrel, and the GPIIbIIIa antagonists in the management of thrombotic disorders.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 1231-1249 |
| Number of pages | 19 |
| Journal | Hematology/Oncology Clinics of North America |
| Volume | 12 |
| Issue number | 6 |
| DOIs | |
| State | Published - Jan 1 1998 |
ASJC Scopus subject areas
- Hematology
- Oncology
Fingerprint Dive into the research topics of 'Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents'. Together they form a unique fingerprint.
Cite this
Calverley, D. C., & Roth, G. J. (1998). Antiplatelet therapy: Aspirin, ticlopidine/clopidogrel, and anti- integrin agents. Hematology/Oncology Clinics of North America, 12(6), 1231-1249. https://doi.org/10.1016/S0889-8588(05)70051-4